Clinical Trial Update: Ranolazine in Ischemic Cardiomyopathy [Phase 4]

View source ↗

Summary

Ranolazine was studied in a Phase 4 trial for ischemic cardiomyopathy; the study completed and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiomyopathy
• Ischemic Cardiomyopathy

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: Midwest Cardiovascular Research Foundation | Conditions: Cardiomyopathy, Chest Pain | Phase 4 | Status: COMPLETED | Results posted: 2018-09-06